Trial
NCT04165031
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Advanced Solid Tumor
Intervention
LY3499446
Why stopped
The study was terminated due to an unexpected toxicity finding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-11-24